Project Grant R56AG096333
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $699K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Troy, NY, USA
Similar Awards
- The National Institute on Aging awarded Arizona State University $431,750 under the Aging Research program (CFDA 93.866) on September 1, 2026, to define the mechanisms underlying the protective effects of the RELN-COLBOS variant in Alzheimer's disease. The funded research leverages stem cell bioengineering, genome editing, and neurodegenerative disease modeling to elucidate the neuroprotective mechanisms of the RELN-COLBOS variant, a rare Reelin variant identified in a PSEN1 mutation carrier...
- The National Institute on Aging awarded the Regenerative Research Foundation $428,175 on February 15, 2026, under the Aging Research program (CFDA 93.866) to develop a human induced pluripotent stem cell (iPSC)-derived three-dimensional vascular microphysiological model for studying cerebral amyloid angiopathy and Alzheimer's disease-related vascular pathology. The recipient will establish a 3D model incorporating microglia and vascular endothelial cells within a microfluidic device to enable...
- The National Institute on Aging awarded Icahn School of Medicine at Mount Sinai $2.944 million on June 1, 2026, under the Aging Research program (CFDA 93.866) to investigate systemic roles of apolipoprotein E (APOE) genotypes in central nervous system health and Alzheimer's disease pathology. The research uses plasma transfer and parabiosis models to examine how blood-borne factors and APOE genotype-specific mediators influence blood-central nervous system neuroimmune communication. The...
- The National Institute on Aging awarded the University of Massachusetts Medical School $419,946 on September 1, 2026, under the Aging Research program (CFDA 93.866) for research into RNA interference-mediated modulation of apolipoprotein E, innate immune response, and tau pathology as a disease-modifying treatment for Alzheimer's disease. The funded research develops and tests small interfering RNA scaffolds that simultaneously target multiple genes implicated in Alzheimer's disease progression....
- The National Institute on Aging awarded $128,250 to Weill Medical College of Cornell University on August 5, 2026, under the Aging Research program (CFDA 93.866) to investigate modifiers of human microglia-neuron interplay in tau propagation in vivo. The research employs a human neuron-microglia chimera platform that integrates human neurons, astrocytes, and microglia into the mouse brain to model Alzheimer's disease and frontotemporal dementia pathology. Aim 1 investigates molecular...
- The National Institute on Aging awarded Albany Medical College $451,000 on September 1, 2026, under the Aging Research program (CFDA 93.866) to identify endothelial gene targets over Alzheimer's disease progression. The research investigates alterations in brain endothelial translatome in Alzheimer's disease and vascular pathology across the progression timeline and in both sexes, addressing a gap in prior studies that were predominantly male or sex-unstratified. The project uses two Alzheimer's...
- The National Institute on Aging awarded the University of Texas Health Science Center at Houston $421,225 on July 1, 2026, under the Aging Research program (CFDA 93.866) to dissect the regulatory mechanism for low-density lipoprotein receptor-related protein 1 using Drosophila vitellogenic oocytes as an in vivo model. The research addresses how LRP1 and related lipid transport receptors regulate amyloid-beta production and clearance and interact with apolipoprotein E4, a primary genetic risk...
- The National Institute on Aging awarded New York University $6.203 million on September 15, 2025, under the Aging Research program (CFDA 93.866) to examine peripheral immune markers and vascular dysfunction as contributors to cognitive decline and Alzheimer's disease. The research integrates circulating biomarkers—platelet aggregation, neutrophil activity, and proteomic data—with advanced imaging to assess associations between vascular and immune dysfunction and cerebrovascular burden, amyloid...
- The National Institute on Aging, part of the Department of Health and Human Services, awarded the University of Texas Medical Branch at Galveston $3.267 million on June 1, 2026, under the Aging Research program (CFDA 93.866). The research investigates the apolipoprotein E (APOE)-tau axis linking preeclampsia to Alzheimer's disease and related neurodegeneration. The project employs primary human trophoblast assays, pre-clinical humanized preeclampsia mouse models, and predictive and therapeutic...
- The National Institute on Aging awarded Brown University $636,372 on June 15, 2026, under the Aging Research program (CFDA 93.866) to support multimodal optical imaging and AI analytics investigating APOE4 etiology and therapeutic targets in late-onset Alzheimer's disease. The research applies label-free optical coherence tomography angiography (OCTA) and two-photon calcium imaging to map vascular topology and flow heterogeneity in APOE4 mice from 12 to 48 weeks of age while tracking...